Katalyze AI, a San Francisco-based life sciences AI startup, has raised $10.5 million in seed funding to build an agentic operating system for pharmaceutical manufacturing and life sciences. The round was led by Bonfire Ventures, with participation from Inovia Capital, Ripple Ventures, Alumni Ventures, Gokul Rajaram, and Farzad Soleimani. The company was founded by Reza Farahani, Shreyas Becker, Hannes Bretschneider, and Matt Cruz.
Katalyze AI’s platform allows scientists and engineers to build specialized AI agents that operate on verified operational data rather than general-purpose AI models. The system integrates production and laboratory data from platforms including MES, LIMS, ELN, and SAP, creating a unified operational record intended for use by both humans and AI agents. Every output remains traceable to its original data source, a feature designed to support compliance in regulated manufacturing environments under Good Manufacturing Practice standards.
The funding comes as pharmaceutical companies face pressure from patent expirations, supply chain constraints, and rising costs associated with bringing new therapies to market. Much of the industry’s research and manufacturing data remains fragmented across disconnected systems, a challenge Katalyze AI aims to address through its integrated, AI-driven approach to pharmaceutical operations.
Featured image: Katalyze AI
